Clinical Trial Update: EXPERT CTO: Evaluation of the XIENCE PRIME™ LL and XIENCE Nano™ Everolimus Eluting Coronary Stent Coronary Stents, Performance, and Technique in Chronic Total Occlusions [NA]

View source ↗

Summary

ClinicalTrials.gov update reports the completed results of the EXPERT CTO study evaluating XIENCE PRIME LL and XIENCE Nano everolimus-eluting coronary stents in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Total Occlusion

Drugs mentioned

• XIENCE Nano (everolimus-eluting coronary stent)
• XIENCE PRIME LL (everolimus-eluting coronary stent)

Snippet

Sponsor: Abbott Medical Devices | Conditions: Coronary Artery Disease (CAD), Chronic Total Occlusion (CTO) | NA | Status: COMPLETED | Results posted: 2014-11-25